Peter D. Meldrum
Algemeen Directeur bij Myriad GmbH
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Walter A. Gilbert | M | 92 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 30 jaar |
S. Phanstiel | F | 65 | 15 jaar | |
David L. Clark | M | 70 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 19 jaar |
Heiner Dreismann | M | 69 | 14 jaar | |
Dale Muzzey | M | 44 | 10 jaar | |
Peter A. Friedli | M | 70 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Lode Debrabandere | M | 59 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Kimberly V. Rogers | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 20 jaar |
Tadashi Hirose | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Chad Bello | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 jaar |
Tracy H. Erkkila | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 23 jaar |
Brad VanWagenen | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 17 jaar |
Paul Robbins | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
Robert R. Becklin | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 jaar |
Nathan Alan Smith | M | - |
Myriad GmbH
Myriad GmbH Medical/Nursing ServicesHealth Services Part of Myriad Genetics, Inc., Myriad GmbH is a German company that provides health care services. The company is based in Munich, Germany. The CEOs of the company are Nathan Alan Smith, Peter D. Meldrum, Raymond Francot. | 6 jaar |
Raymond Francot | M | 61 |
Myriad GmbH
Myriad GmbH Medical/Nursing ServicesHealth Services Part of Myriad Genetics, Inc., Myriad GmbH is a German company that provides health care services. The company is based in Munich, Germany. The CEOs of the company are Nathan Alan Smith, Peter D. Meldrum, Raymond Francot. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
R. Riggsbee | M | 53 | 10 jaar | |
Mark Capone | M | 61 | 18 jaar | |
John Henderson | M | 79 | 16 jaar | |
Benjamin Jackson | M | 45 | - | |
Mark H. Skolnick | M | 78 | - | |
James S. Evans | M | 61 | 19 jaar | |
Brad D. Hardy | M | - |
University of Utah
| 5 jaar |
Lawrence C. Best | M | 75 | 11 jaar | |
R. Bruce Merrell | M | 78 |
University of Utah
| 6 jaar |
Alan C. Kay | M | 84 |
University of Utah
| 3 jaar |
Carl E. Brechtel | M | 74 |
University of Utah
| 5 jaar |
Alan C. Ashton | M | - |
University of Utah
| 8 jaar |
Wallace T. Boyack | M | 81 |
University of Utah
| 4 jaar |
Brent J. Giauque | M | - |
University of Utah
| 6 jaar |
Rebecca Chambers | F | 46 | 1 jaar | |
Lynn C. Miller | M | - |
University of Utah
| 1 jaar |
Randall W. Burt | M | - |
University of Utah
| 4 jaar |
James L. McCarrey | M | - |
University of Utah
| 6 jaar |
Kent H. Murdock | M | - |
University of Utah
| 7 jaar |
Kem C. Gardner | M | - |
University of Utah
| 7 jaar |
Gregory Goff | M | 67 |
University of Utah
| 7 jaar |
Christopher Aadnesen | M | 75 |
University of Utah
| 4 jaar |
Dennis Langer | M | 73 | 18 jaar | |
William A. Hockett | M | 67 | - | |
Richard M. Marsh | M | 65 | 17 jaar | |
David E. Dangerfield | M | 83 |
University of Utah
| 5 jaar |
Gary F. Kennedy | M | 69 |
University of Utah
| 7 jaar |
William D. Kyle | M | 78 |
University of Utah
| 1 jaar |
Eugene Spiering | M | 70 |
University of Utah
| 6 jaar |
L. John Lewis | M | 74 |
University of Utah
| 4 jaar |
Fred W. Fairclough | M | 74 |
University of Utah
| 4 jaar |
Jon Methew Witkin | M | 70 |
University of Utah
| 4 jaar |
Tracy Stevenson | M | 73 |
University of Utah
| 4 jaar |
Richard J. Wenstrup | M | - | 2 jaar | |
Alexander Ford | M | - | 10 jaar | |
Glenn D. Warden | M | - |
University of Utah
| 3 jaar |
Randall J. Petersen | M | - |
University of Utah
| 4 jaar |
Ed T. Alter | M | - |
University of Utah
| 8 jaar |
Jeffrey W. Holmes | M | 70 |
University of Utah
| 4 jaar |
Tim Howells | M | - |
University of Utah
| 4 jaar |
Alan E. Nugent | M | 79 |
University of Utah
| 4 jaar |
David Aldous | M | 67 |
University of Utah
| 6 jaar |
Yvonne Campos | F | - |
University of Utah
| 1 jaar |
Russell Gentner | M | - |
University of Utah
| 4 jaar |
Terry O'Neill | F | 79 |
University of Utah
| 3 jaar |
David John Thomas | M | 80 |
University of Utah
| 4 jaar |
Andrew W. Smith | M | 72 |
University of Utah
| 4 jaar |
Craig Foster Pickett | M | - |
University of Utah
| 4 jaar |
Michael Ray Herrington | M | - |
University of Utah
| 4 jaar |
Gordon Kirkham | M | - |
University of Utah
| 4 jaar |
James E. Carter | M | - |
University of Utah
| 3 jaar |
Jane E. Judd | F | 77 |
University of Utah
| 4 jaar |
Scott Gleason | M | 45 | - | |
James Earl Solomon | M | 73 |
University of Utah
| 4 jaar |
James H. Clark | M | 80 |
University of Utah
| 3 jaar |
Kirk Blosch | M | 69 |
University of Utah
| 4 jaar |
Terry C. Turner | M | 72 |
University of Utah
| 4 jaar |
Gary D. Kennedy | M | - |
University of Utah
| 3 jaar |
Michael T. Bebon | M | - |
University of Utah
| 2 jaar |
Michael Giordano | M | 77 |
University of Utah
| 2 jaar |
Larry Hendricks | M | 81 |
University of Utah
| 1 jaar |
Gregg B. Colton | M | 71 |
University of Utah
| 4 jaar |
Robert S. Attiyeh | M | 90 | 6 jaar | |
Mitchell T. Godfrey | M | 78 |
University of Utah
| 4 jaar |
Robert W. Cunningham | M | - |
University of Utah
| 4 jaar |
Edward B. Wilson | M | - |
University of Utah
| 4 jaar |
Thomas L. Harkness | M | 78 |
University of Utah
| 4 jaar |
Denny W. Nestripke | M | 76 |
University of Utah
| 4 jaar |
R. Matthew Shino | M | - |
University of Utah
| 6 jaar |
Howard S. Landa | M | 77 |
University of Utah
| 4 jaar |
Robert Harrison | M | 57 | 25 jaar | |
Adrian N. Hobden | M | 71 | - | |
Charles D. Ebert | M | 70 |
University of Utah
| 4 jaar |
Steven C. Oldham | M | 73 |
University of Utah
| 4 jaar |
Larry Shaw | M | - |
University of Utah
| 4 jaar |
David M. Mock | M | 71 |
University of Utah
| 4 jaar |
Michael S. Anderson | M | 70 |
University of Utah
| 4 jaar |
Ronald G. Moffitt | M | - |
University of Utah
| 4 jaar |
Randall MacKey | M | 77 |
University of Utah
| 4 jaar |
Steve Atkinson | M | - |
University of Utah
| 2 jaar |
Robert Whitman | M | 71 |
University of Utah
| 4 jaar |
Michael M. Lloyd | M | - |
University of Utah
| 4 jaar |
F. Briton McConkie | M | - |
University of Utah
| 4 jaar |
Norman Cocke | M | - |
University of Utah
| 2 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 98 | 98.00% |
Duitsland | 2 | 2.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Peter D. Meldrum
- Persoonlijk netwerk